Shares of Aktis Oncology (NASDAQ:AKTS – Get Free Report) shot up 6.1% during trading on Tuesday . The company traded as high as $29.01 and last traded at $28.1850. 43,845 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 338,937 shares. The stock had previously closed at $26.56.
Wall Street Analysts Forecast Growth
AKTS has been the subject of several research analyst reports. HC Wainwright lifted their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Weiss Ratings upgraded Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Raymond James Financial initiated coverage on Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price for the company. Finally, William Blair started coverage on Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.
View Our Latest Analysis on AKTS
Aktis Oncology Trading Up 4.0%
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last released its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The firm had revenue of $1.87 million for the quarter. On average, equities research analysts forecast that Aktis Oncology will post -1.62 earnings per share for the current year.
Aktis Oncology Company Profile
Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.
The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.
Read More
- Five stocks we like better than Aktis Oncology
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
